IRadimed Co. (NASDAQ:IRMD – Get Rating) Director Monty K. Allen sold 3,072 shares of IRadimed stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $37.71, for a total value of $115,845.12. Following the completion of the sale, the director now directly owns 16,928 shares in the company, valued at approximately $638,354.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
IRadimed Price Performance
NASDAQ:IRMD opened at $37.52 on Friday. IRadimed Co. has a 1 year low of $28.90 and a 1 year high of $55.92. The stock’s 50 day simple moving average is $34.87 and its two-hundred day simple moving average is $39.93. The company has a market cap of $471.25 million, a price-to-earnings ratio of 38.68 and a beta of 0.98.
Institutional Trading of IRadimed
A number of large investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System bought a new stake in IRadimed in the 2nd quarter worth approximately $270,000. Aviva PLC boosted its holdings in shares of IRadimed by 334.5% in the 2nd quarter. Aviva PLC now owns 61,259 shares of the medical equipment provider’s stock worth $2,079,000 after purchasing an additional 47,159 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of IRadimed by 12.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 246,264 shares of the medical equipment provider’s stock worth $8,356,000 after purchasing an additional 27,059 shares during the period. Dupont Capital Management Corp purchased a new position in shares of IRadimed in the 2nd quarter worth approximately $359,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of IRadimed by 16.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 65,573 shares of the medical equipment provider’s stock worth $2,225,000 after purchasing an additional 9,255 shares during the period. Institutional investors own 39.86% of the company’s stock.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.
- Get a free copy of the StockNews.com research report on IRadimed (IRMD)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.